Sarah Smith

Sarah Smith

Expertise: ESG Investing, Electric Vehicle Stocks, Short Squeeze Stocks

Education: BA, Government and Gender, Sexuality and Women’s Studies, The College of William & Mary

Awards & Accomplishments: Top 5% of stock pickers on TipRanks

About Sarah:
Sarah Smith is an experienced editor and writer who works to help retail investors make sense of what’s happening every day on Wall Street, and she’s particularly interested in ESG investing, EV stocks, and the rise of speculative trading activity like short squeezes. She has also written for Kiplinger.com, Smithsonian, and Washington City Paper. Sarah is currently working to become a Chartered Financial Analyst (CFA) and has already earned bachelor’s degrees in Government and Gender, Sexuality and Women’s Studies from the College of William and Mary. Her work for InvestorPlace.com focuses on helping investors understand the causes and impacts of daily stock and crypto market movements, and how a disruption in who invests – and how they invest – transforms the market. Sarah is recognized among the top 5% of stock pickers on TipRanks and has an average return of 50%. She lives in Arlington, Virginia.

Connect with Sarah on LinkedIn.

Recent Articles

HCCH Stock: 12 Things to Know Ahead of the Fusion Fuel SPAC Merger

What should you know about HCCH stock as HL Acquisitions closes it merger with Fusion Fuel? Dive into the hydrogen play here.

QS Stock: Why QuantumScape Shares Are Surging Today

QS stock is surging Tuesday morning after QuantumScape shared impressive results on its solid-state battery technology.

Autonomous Vehicle Stocks: Why LAZR, CGRO and VLDR Stock Are Climbing Today

VLDR stock is joining Luminar and Collective Growth in recent success thanks to its role with LiDAR sensors.

SPCE Stock: Why Virgin Galactic Stock Is Rocketing Higher Today

SPCE stock is rocketing higher Monday thanks to speculation that Virgin Galactic could soon be launching its test flight.

Palantir Stock Surges on FDA Contract Victory

PLTR stock is surging even higher after Palantir just landed a three-year contract with the U.S. Food and Drug Administration.